Cargando…

The COVID-19 Pandemic Is Associated with Reduced Survival after Pancreatic Ductal Adenocarcinoma Diagnosis: A Single-Centre Retrospective Analysis

The COVID-19 pandemic has hugely disrupted healthcare provision, including oncology services. To evaluate the effects of the pandemic on referral routes leading to diagnosis, treatments, and prognosis in patients with pancreatic ductal adenocarcinoma, we performed a retrospective cohort study at a s...

Descripción completa

Detalles Bibliográficos
Autores principales: Madge, Oliver, Brodey, Alexandra, Bowen, Jordan, Nicholson, George, Sivakumar, Shivan, Bottomley, Matthew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105306/
https://www.ncbi.nlm.nih.gov/pubmed/35566700
http://dx.doi.org/10.3390/jcm11092574
_version_ 1784708008151875584
author Madge, Oliver
Brodey, Alexandra
Bowen, Jordan
Nicholson, George
Sivakumar, Shivan
Bottomley, Matthew J.
author_facet Madge, Oliver
Brodey, Alexandra
Bowen, Jordan
Nicholson, George
Sivakumar, Shivan
Bottomley, Matthew J.
author_sort Madge, Oliver
collection PubMed
description The COVID-19 pandemic has hugely disrupted healthcare provision, including oncology services. To evaluate the effects of the pandemic on referral routes leading to diagnosis, treatments, and prognosis in patients with pancreatic ductal adenocarcinoma, we performed a retrospective cohort study at a single tertiary centre in the UK. The patients were identified from the weekly hepatopancreatobiliary multidisciplinary team meetings between February 2018 and March 2021. The demographic, referral, and treatment data for each patient and date of death, where applicable, were extracted from the electronic patient record. The patients (n = 203) were divided into “pre-pandemic” and “pandemic” cohorts based on a referral date cut-off of 23rd March 2020. The median survival was 7.4 months [4.9–9.3] in the “pre-pandemic” cohort (n = 125), halving to 3.3 months [2.2–6.0], (p = 0.015) in the “pandemic” cohort (n = 78). There was no significant difference in patient characteristics between the two cohorts. There was a trend toward increased emergency presentations at diagnosis and reduced use of surgical resection in the “pandemic” cohort. This small-scale study suggested that the COVID-19 pandemic is associated with a halving of median survival in pancreatic ductal adenocarcinoma. Urgent further studies are required to confirm these findings and examine corresponding effects in other cancer types.
format Online
Article
Text
id pubmed-9105306
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-91053062022-05-14 The COVID-19 Pandemic Is Associated with Reduced Survival after Pancreatic Ductal Adenocarcinoma Diagnosis: A Single-Centre Retrospective Analysis Madge, Oliver Brodey, Alexandra Bowen, Jordan Nicholson, George Sivakumar, Shivan Bottomley, Matthew J. J Clin Med Article The COVID-19 pandemic has hugely disrupted healthcare provision, including oncology services. To evaluate the effects of the pandemic on referral routes leading to diagnosis, treatments, and prognosis in patients with pancreatic ductal adenocarcinoma, we performed a retrospective cohort study at a single tertiary centre in the UK. The patients were identified from the weekly hepatopancreatobiliary multidisciplinary team meetings between February 2018 and March 2021. The demographic, referral, and treatment data for each patient and date of death, where applicable, were extracted from the electronic patient record. The patients (n = 203) were divided into “pre-pandemic” and “pandemic” cohorts based on a referral date cut-off of 23rd March 2020. The median survival was 7.4 months [4.9–9.3] in the “pre-pandemic” cohort (n = 125), halving to 3.3 months [2.2–6.0], (p = 0.015) in the “pandemic” cohort (n = 78). There was no significant difference in patient characteristics between the two cohorts. There was a trend toward increased emergency presentations at diagnosis and reduced use of surgical resection in the “pandemic” cohort. This small-scale study suggested that the COVID-19 pandemic is associated with a halving of median survival in pancreatic ductal adenocarcinoma. Urgent further studies are required to confirm these findings and examine corresponding effects in other cancer types. MDPI 2022-05-04 /pmc/articles/PMC9105306/ /pubmed/35566700 http://dx.doi.org/10.3390/jcm11092574 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Madge, Oliver
Brodey, Alexandra
Bowen, Jordan
Nicholson, George
Sivakumar, Shivan
Bottomley, Matthew J.
The COVID-19 Pandemic Is Associated with Reduced Survival after Pancreatic Ductal Adenocarcinoma Diagnosis: A Single-Centre Retrospective Analysis
title The COVID-19 Pandemic Is Associated with Reduced Survival after Pancreatic Ductal Adenocarcinoma Diagnosis: A Single-Centre Retrospective Analysis
title_full The COVID-19 Pandemic Is Associated with Reduced Survival after Pancreatic Ductal Adenocarcinoma Diagnosis: A Single-Centre Retrospective Analysis
title_fullStr The COVID-19 Pandemic Is Associated with Reduced Survival after Pancreatic Ductal Adenocarcinoma Diagnosis: A Single-Centre Retrospective Analysis
title_full_unstemmed The COVID-19 Pandemic Is Associated with Reduced Survival after Pancreatic Ductal Adenocarcinoma Diagnosis: A Single-Centre Retrospective Analysis
title_short The COVID-19 Pandemic Is Associated with Reduced Survival after Pancreatic Ductal Adenocarcinoma Diagnosis: A Single-Centre Retrospective Analysis
title_sort covid-19 pandemic is associated with reduced survival after pancreatic ductal adenocarcinoma diagnosis: a single-centre retrospective analysis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9105306/
https://www.ncbi.nlm.nih.gov/pubmed/35566700
http://dx.doi.org/10.3390/jcm11092574
work_keys_str_mv AT madgeoliver thecovid19pandemicisassociatedwithreducedsurvivalafterpancreaticductaladenocarcinomadiagnosisasinglecentreretrospectiveanalysis
AT brodeyalexandra thecovid19pandemicisassociatedwithreducedsurvivalafterpancreaticductaladenocarcinomadiagnosisasinglecentreretrospectiveanalysis
AT bowenjordan thecovid19pandemicisassociatedwithreducedsurvivalafterpancreaticductaladenocarcinomadiagnosisasinglecentreretrospectiveanalysis
AT nicholsongeorge thecovid19pandemicisassociatedwithreducedsurvivalafterpancreaticductaladenocarcinomadiagnosisasinglecentreretrospectiveanalysis
AT sivakumarshivan thecovid19pandemicisassociatedwithreducedsurvivalafterpancreaticductaladenocarcinomadiagnosisasinglecentreretrospectiveanalysis
AT bottomleymatthewj thecovid19pandemicisassociatedwithreducedsurvivalafterpancreaticductaladenocarcinomadiagnosisasinglecentreretrospectiveanalysis
AT madgeoliver covid19pandemicisassociatedwithreducedsurvivalafterpancreaticductaladenocarcinomadiagnosisasinglecentreretrospectiveanalysis
AT brodeyalexandra covid19pandemicisassociatedwithreducedsurvivalafterpancreaticductaladenocarcinomadiagnosisasinglecentreretrospectiveanalysis
AT bowenjordan covid19pandemicisassociatedwithreducedsurvivalafterpancreaticductaladenocarcinomadiagnosisasinglecentreretrospectiveanalysis
AT nicholsongeorge covid19pandemicisassociatedwithreducedsurvivalafterpancreaticductaladenocarcinomadiagnosisasinglecentreretrospectiveanalysis
AT sivakumarshivan covid19pandemicisassociatedwithreducedsurvivalafterpancreaticductaladenocarcinomadiagnosisasinglecentreretrospectiveanalysis
AT bottomleymatthewj covid19pandemicisassociatedwithreducedsurvivalafterpancreaticductaladenocarcinomadiagnosisasinglecentreretrospectiveanalysis